Recent research has showed alpha4beta2 receptor activation represent a primary molecular target for neuroprotection. Laudanosine, a metabolite of the neuromuscular blocking drugs atracurium and cisatracurium can activate central alpha4beta2 receptors. As a consequence, it was hypothesized that laudanosine, at clinical concentrations reported in the CSF during and up to several hours after the end of neurosurgery, might elicit a long-acting neuroprotective action.
Potential neuroprotective properties of atracurium and cisatracurium in neurosurgical anaesthesia.
FODALE, Vincenzo;SANTAMARIA, Letterio
2004-01-01
Abstract
Recent research has showed alpha4beta2 receptor activation represent a primary molecular target for neuroprotection. Laudanosine, a metabolite of the neuromuscular blocking drugs atracurium and cisatracurium can activate central alpha4beta2 receptors. As a consequence, it was hypothesized that laudanosine, at clinical concentrations reported in the CSF during and up to several hours after the end of neurosurgery, might elicit a long-acting neuroprotective action.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
